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Abstract: Gaucher disease is a rare inborn error of glycosphingolipid metabolism due to 
deficiency of lysosomal acid β-glucocerebrosidase; the condition has totemic significance for 
the development of orphan drugs. A designer therapy, which harnesses the mannose recep-
tor to complement the functional defect in macrophages, ameliorates the principal clinical 
manifestations in hematopoietic bone marrow and viscera. While several aspects of Gaucher 
disease (particularly those affecting the skeleton and brain) are refractory to treatment, enzyme 
  (replacement) therapy has become a pharmaceutical blockbuster. Human β-glucocerebrosidase 
was originally obtained from placenta and the Genzyme Corporation (Allston, MA)   subsequently 
developed a recombinant product. After purification, the enzyme is modified to reveal terminal 
mannose residues which facilitate selective uptake of the protein, imiglucerase (Cerezyme®), 
in macrophage-rich tissues. The unprecedented success of Cerezyme has attracted fierce com-
petition: two biosimilar agents, velaglucerase-alfa, VPRIV® (Shire Human Genetic Therapies, 
Dublin, Ireland) and taliglucerase-alfa (Protalix, Carmiel, Israel), are now approved or in 
late-phase clinical development as potential ‘niche busters’. Oral treatments have advantages 
over biological agents for disorders requiring lifelong therapy and additional stratagems which 
utilize small, orally active molecules have been introduced; these include two chemically distinct 
compounds which inhibit uridine diphosphate glucose: N-acylsphingosine glucosyltransferase, 
the first step in the biosynthesis of glucosylceramide – a key molecular target in Gaucher 
disease and other glycosphingolipidoses. Academic and commercial enterprises in biotechnol-
ogy have combined strategically to expand the therapeutic repertoire in Gaucher disease. The 
innovative potential of orphan drug legislation has been realized – with prodigious rewards for 
companies embracing its humanitarian precepts. In the era before enzyme therapy, bone mar-
row transplantation was shown to correct systemic disease in Gaucher patients by supplying a 
source of competent donor macrophages. As a radical advance on cell- or protein-replacement 
techniques, contemporary methods for transferring genes to autologous hematopoietic stem 
cells, and to the brain, merit further exploration. At present, the inflated pharmaceutical niche 
of Gaucher disease appears to be resilient, but if the remaining unmet needs of patients are to 
be convincingly addressed and commercial development sustained, courageous scientific invest-
ment and clinical   experimentation will be needed.
Keywords: Gaucher disease, orphan diseases, lysosome, macrophage, enzyme therapy, substrate 
inhibitors, enzyme replacement
Clinical profile
Gaucher disease was the first lysosomal disease for which a specific therapy was introduced 
in the US orphan legislative milieu. The success of Ceredase and Cerezyme (Genezyme 
Corporation, Allston, MA) has driven pharmaceutical investment in other lysosomal Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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diseases which have disabling effects on life quality and 
survival. A contemporary Western dilemma rests between 
the provision of high-cost medicines requiring intensive 
investment for very few patients and the corporate invest-
ment required to improve the health of the population by a 
more radical attack on the causes of   common illness.1
Gaucher disease
Definition
Gaucher disease is caused by a functional deficiency of the 
acid hydrolase, β-glucocerebrosidase, or glucosylcerami-
dase (E.C.3.2.1.45).2,3 The immediate substrates for this 
enzyme are glucosylceramide and its nonacylated analog, 
glucosylsphingosine. These glycosphingolipids arise from 
the digestion of more complex glucosides and gangliosides 
present in cell membranes. Rare variant forms of Gaucher 
disease result from deficiency of the sphingolipid activator 
protein, saposin C.3 Latterly, inherited defects in a recently 
discovered molecule, LIMP-2, have been associated with 
an usual phenotype with β-glucocerebrosidase deficiency 
in the kidney, brain, and other tissues, but not white cells or 
macrophages, in which it serves as a chaperone for delivery 
of nascent glucocerebrosidase polypeptide to the lysosomal 
compartment.4–6
Gaucher disease most obviously affects cells of mono-
nuclear phagocyte lineage in which prominent storage of 
undegraded lipids occurs (see Figure 1); mutations in the 
gene (GBA1) which encodes human β-glucocerebrosidase 
may disable the protein sufficiently to disturb its enzymatic 
function in other cell lineages, including those of the nervous 
system and the skin, which may become diseased.3
Clinical manifestations
Gaucher disease may occur at any age and in any 
human population.3,7–9 Certain forms of the condition are 
over-represented in patients of Ashkenazi Jewish ancestry 
and in a small inbred population in Northern Sweden. 
For practical purposes, the condition has been classified 
into three principal ‘types’. The most frequent form of 
the condition (affecting ∼90% of patients and assigned as 
type I) is associated with subtotal deficiency of lysosomal 
acid β-glucocerebrosidase and manifestations principally 
in the viscera (principally liver and spleen, see Figure 2) 
as well as bone marrow, which are infiltrated by pathologi-
cal macrophages (Gaucher cells, Figure 1) engorged with 
glucosylceramide and other sphingolipids. Many mutations 
responsible for the enzymatic deficiency have been identified 
in the glucocerebrosidase gene; those with severe effects on 
enzymatic activity are associated with various neurological 
manifestations and coinheritance of severe defects in the 
gene with almost complete lack of glucocerebrosidase, 
which is a rare cause of stillbirth with skeletal deformities 
and/or dehydration as a result of abnormal skin integrity 
(collodion babies). An acute form of neurological illness 
(for convenience classified as type II Gaucher disease but 
effectively a condition with neuronopathic features that are 
not slowly progressive, as in type III) is a very rare disorder 
causing death in the first years of life; characteristically, 
there is irritability, bulbar palsies,   opisthotonus, and modest 
enlargement of the viscera.
Type I Gaucher disease is generally associated with 
prominent visceral and skeletal manifestations. Splenic 
pooling of formed elements of the blood leads to cytope-
nias with bleeding due to low platelet count, anemia, and 
risk of infection due to leukopenia. There may be massive 
enlargement of the liver and spleen (Figure 2) and occa-
sionally severe infiltration of the lungs by pathological 
macrophages.
It is noteworthy that in the past, type I Gaucher disease 
was defined as being free of neurological manifestations, 
Figure 1 Pelvis, hips, and upper femora of adult Gaucher patient. Figure 2 Gaucher spleen .3 kg with large recent infarct.Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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but increasingly it has been shown that patients develop 
an extrapyramidal disease resembling Parkinsonism in 
middle life, the cause of which is not understood. More-
over, it is now known that mutations in the human GBA1 
gene, present in the heterozygous state in individuals of 
numerous ethnic origins and not hitherto identified as suf-
fering from   Gaucher disease, are the most prevalent genetic 
determinants of   Parkinson’s disease so far identified in 
many populations.10
Type I Gaucher patients have enlarged viscera which 
are infiltrated by alternatively activated macrophages 
which are typically found in the sinusoids of the spleen 
and replace the Kupffer cells of the liver. The macrophages 
are prominent in the bone marrow and contribute to acute 
episodes of osteonecrosis, particularly during growth. 
Necrosis of the marrow in proximity leads to impaired 
function of large joints, including the hip, knee, and 
shoulder. Other effects on the skeleton include local 
swellings   (Gaucheromas) and destruction of bone in 
osteolytic lesions, as well as   generalized demineralization 
and osteoporosis with an accompanying risk of fragility 
fractures (see Figure 3).
Less than 10% of patients with Gaucher disease develop 
a chronic so-called neuronopathic form, formerly termed 
type III Gaucher disease, with visual gaze palsies and other 
manifestations including myoclonic epilepsy and nerve deaf-
ness – all of which may be complicated by variable systemic 
involvement and at times prominent alveolar infiltration of 
the lungs.
Although Gaucher disease may declare itself at any age, 
in general, presentation in infancy and childhood carries a 
worse prognosis. There is a progressive deformity of the 
skeleton, enlargement of the viscera, and impaired function 
of organs, often accompanied by painful complications of 
skeletal disease. The condition shortens life, and even patients 
who present in late middle life ultimately may succumb. 
A rare complication of the condition is the development of 
hematological malignancies, most characteristically B-cell 
lymphomas and multiple myeloma, the pathogenesis of 
which is incompletely understood. Untreated Gaucher disease 
leads to progressive misery associated with bleeding, pallor, 
and anemia, together with visceral enlargement and bone 
pain; it is associated with disability and markedly reduced 
life quality, as well as survival.
Frequency
The birth frequency of Gaucher disease is ∼1:60,000 live 
births in the general population,11 but genetic studies indicate 
a homozygote frequency of ∼1:950 Ashkenazi Jews, many of 
whom appear to remain asymptomatic.12 In most countries, 
there is a marked discrepancy between the predicted and the 
observed prevalence: with a population of more than 60 mil-
lion in the UK, only about 300 patients with Gaucher disease 
are known, giving an operational prevalence figure of about 
1 in 200,000 – very much less than the predicted frequency 
at birth.8 It can readily be seen that the disease is much less 
common than the threshold for designation as an orphan 
disorder in any country (eg, with a prevalence ,1 in 2000 
in Europe or ,200,000 individuals in the United States); 
with ,1 in 50,000 affected persons in the UK, the new term, 
‘ultraorphan,’ has been suggested.
Diagnosis of Gaucher disease
The condition may be suspected in any patient with unex-
plained splenomegaly, particularly those of Ashkenazi 
  Jewish origin.3,8,12 Gaucher disease may also come to light as 
a result of investigations for pancytopenia or visceromegaly; 
thus Gaucher cells may be identified on tissue biopsy speci-
mens, principally of bone marrow (during investigations for 
splenomegaly or cytopenias) or liver (during the course of 
investigations for hepatomegaly or abnormal liver-related 
biochemical tests). It is worth emphasizing that the presence 
of abnormal macrophages with the appearance of Gaucher 
cells is not sufficient for the diagnosis since these may be 
observed in other hematological conditions such as chronic 
myeloid leukemia, thalassemia, and multiple myeloma – the 
last named itself a rare complication of Gaucher disease. 
Specific diagnosis is, however, made by measuring acid 
β-glucosidase activity in fresh peripheral blood leuko-
cytes, or occasionally by enzymatic analysis of fibroblasts  Figure 3 Pathological macrophages in bone marrow.Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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cultured from skin biopsy specimens. Confirmation and 
better characterization of the condition may subsequently 
be afforded by molecular analysis of the human GBA1 gene, 
which encodes lysosomal glucocerebrosidase. The disorder 
may be suggested by a history of Perthés disease or as 
a result of radiological investigations which show bone 
deformity in the long bones due to a modeling defect, 
designated the Erlenmeyer flask abnormality, in the distal 
femur or proximal tibia.
Pathogenesis
In classical descriptions of the condition, although engorged 
macrophages represent the pathognomonic focus of   Gaucher 
disease, the simple presence of storage material within 
these infiltrating cells provides an incomplete   explanation 
of   causation. Storage material accumulating within the 
macrophages accounts for a fraction of the massive bulk 
of the organs, which show macrophage hyperplasia and 
  hypertrophy. While the pathological macrophages are accom-
panied by vascular changes and fibrosis, for example within 
the liver and spleen, they are not prominent in the brain 
in patients with neurological manifestations. More likely, 
abnormal storage material and other chemical changes 
within cells induce release of inflammatory factors, includ-
ing chemokines and cytokines, which lead to the cascade of 
pathological changes.3,13–20   Complex mechanisms, including 
abnormal calcium pooling within neural cell compartments, 
have been invoked, particularly in the neurological manifes-
tations which characterize the severe Gaucher variants.18,19 
Some authorities consider that the water-soluble lysolipid, 
glucosylsphingosine, has far-reaching signaling effects and 
may be responsible for cell death.13,16,17 Quasipathophysi-
ological concentrations of glucosylsphingosine affect the 
function of intracellular actin and induce a defect of cytoki-
nesis generating a Gaucher-like phenotype on exposure of 
cultured macrophage cell lines to the molecule.20
Therapeutics of Gaucher disease
Until the 1990s, no specific or curative treatments for most 
patients with Gaucher disease were available. Supportive and 
palliative measures include orthopedic interventions such as 
joint replacement surgery and occasional hepatic transplanta-
tion. Splenectomy was widely used to overcome the effects 
of hypersplenism in the blood, but carries with it immediate 
and long-term risks of overwhelming microbial infection;21 
splenectomy also contributes to the risk of osteonecrosis in 
Gaucher disease.22
Cellular complementation
Given the visceral infiltration by pathological mac-
rophages, which are of hematopoietic origin, bone marrow 
  transplantation has been attempted in Gaucher disease.23 
Successful engraftment given before the development of 
irreversible skeletal and organ changes may correct the 
disease by replacing the defective macrophages with those 
of healthy donor origin. Children with the chronic neuronop-
athic form of Gaucher disease (type III), particularly those of 
Norrbottnian origin, had an improvement in their health but 
no apparent correction of the neurological disorder, despite a 
repopulation of microglia in the brain slowly by mononuclear 
cells of hematopoietic origin.24,25
Bone marrow and contemporary hematopoietic stem-cell 
transplantation is not in current general use for Gaucher dis-
ease, partly because of the shortage of ideal donors (human 
leukocyte antigen matched) and procedural risks, as well 
as the introduction of successful enzymatic augmentation 
which has superseded this treatment in many countries. The 
author treats one patient, the first male to receive allogeneic 
bone marrow transplantation in 1984 at the age of 11 years; 
homozygous for the L444P allele of the human glucocerebro-
sidase gene, the patient has type III disease with lateral gaze 
palsy and severe skeletal abnormalities following removal 
of a massive spleen aged 2 years. No longer confined to a 
wheelchair and with complete donor chimerism, the patient 
is now working independently as a farmer and drives a tractor 
unaided; he has no clinical or hematologic signs of Gaucher 
disease, which is inactive in the viscera and skeleton. From 
this case and a few others reported, it is clear that most, if 
not all, key aspects of the systemic disease are due to defec-
tive cells of mononuclear phagocytic lineage and thus may 
be corrected by supplying healthy exogenous hematopoietic 
stem cells or by transducing autologous stem cells with vec-
tors for transferring the wild-type human glucocerebrosidase 
gene in order to restore the capacity of tissue macrophages 
to digest glycolipids normally.
enzymatic augmentation
Soon after the enzymatic defect in Gaucher disease was 
identified in the 1960s, a long program of work into enzy-
matic replacement was initiated. At the time, studies on the 
hepatic uptake of plasma glycoproteins by Ashwell and 
Morell had been shown to be related to lectin-like activ-
ity of cellular receptors.26 A further body of work showed 
that uptake of proteins by macrophages occurred through a 
surface receptor recognizing terminal mannose residues on Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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protein ligands.27 Early attempts to correct the biochemical 
abnormalities of Gaucher disease in patients after infusion 
of purified human glucocerebrosidase prepared from human 
placentae met with scant success, but it was later shown 
that the enzyme from human placentae contained enzyme 
  molecules with complex carbohydrate chains, and mostly 
with terminal sialic acid   residues.28 In key experiments, 
it was later shown that sequential removal of sialic acid, 
galactose, and N-acetylglucosamine using exoglycosidases 
prepared from plant sources yielded a molecular form of the 
enzyme that was avidly taken up by Kupffer cells and other 
preparations of macrophages.29
This finding formed the basis of further clinical trials of 
mannosylated glucocerebrosidase in Gaucher patients – one of 
whom, a small boy, showed a striking improvement in red-cell 
and platelet counts with a substantial reduction in spleen size.30 
A remarkable collaboration between a patient organization 
(the National Gaucher Foundation), the National Institutes of 
Health, where Dr. Roscoe Brady and his colleagues were work-
ing, and a newly formed company, the Genzyme Corporation, 
led to a clinical trial involving 12 patients with type I Gaucher 
disease. The participants were studied for 6 months during a 
course of infusions of modified human placental glucocer-
ebrosidase given every 2 weeks. A large dose of the enzyme 
was administered (60 IU/kg of body weight every 2 weeks), 
and in the event, all the trial participants showed beneficial 
responses in terms of blood count and visceral parameters.31 
Mannose-terminated human placental glucocerebrosidase, 
later known as alglucerase (Ceredase®; Genzyme Corporation, 
Cambridge, MA), was licensed under the special regulations 
introduced through the orphan drug legislation in the United 
States. It was notable that the trial, which was an open-label 
trial without a control arm, showed clear benefit on spleen size 
in those patients studied.31 As indicated above, since the splenic 
enlargement with hypersplenism is a central determinant of the 
illness in Gaucher disease and splenectomy can be avoided if 
the spleen size is decreased, this pivotal clinical trial clearly 
addressed an unmet clinical need. At the same time, the use of 
glucocerebrosidase derived from pooled human tissues (many 
thousands of human placentae were required for the produc-
tion of sufficient Ceredase to treat a single Gaucher patient) 
posed considerable risk at a time when biological agents 
derived from human tissues were a known source of hepatitis 
viruses and HIV and were implicated in the transmission of 
the Creutzfeldt–Jakob agent. Nonetheless, numerous patients 
worldwide were treated with alglucerase under license, with 
salutary effects on quality of life, as well as improved blood 
counts, the regression of visceromegaly, and a decreased 
  frequency of osteonecrosis episodes and reported bone pain.
Genetically engineered enzymatic augmentation
Approximately 5 years after the licensing of alglucerase, the 
Genzyme Corporation launched Cerezyme, imiglucerase – a 
recombinant human glucocerebrosidase expressed in geneti-
cally engineered Chinese hamster ovary cells. As with the 
purified placental product, this enzyme required further 
modification by exoglycosidases to expose glycan residues 
which mediate delivery to tissue macrophages utilizing the 
lectin-like properties of membrane mannose receptors.
Imiglucerase has now been given to more than 5000 
patients worldwide and clearly reverses many of the mani-
festations of Gaucher disease, particularly those affecting the 
bone marrow and viscera.32 In adults and children, there is a 
salutary increase in hemoglobin concentration, and white cell, 
and platelet counts, with a decrease in surrogate biomarkers 
of disease activity – certain macrophage-related proteins 
are released abundantly into the circulation in response to 
cellular storage.33,34
Tissue sampling, which is not routinely performed, 
demonstrates a reduction in the number of pathological mac-
rophages infiltrating bone marrow and liver tissue. Although 
episodes of osteonecrosis become less frequent in patients 
receiving enzyme therapy and salutary improvements in bone 
mineralization density have been demonstrated in those with 
osteopenia and osteonecrosis, it is not surprising that those 
manifestations related to tissue and bone injury before treat-
ment is instigated cannot be corrected.35 While as a whole, 
the clinical evidence points strongly to disease-modifying 
properties of enzyme therapy in Gaucher disease, it is unclear 
as to whether it reduces the risk of B-cell malignancies and 
myeloma in patients with Gaucher disease. Moreover, any 
relationship of enzyme therapy to the development of the 
Parkinsonian complications of Gaucher disease has yet to 
be explored. Despite these reservations, enzyme replace-
ment therapy for Gaucher disease with alglucerase and 
imiglucerase has been a signal therapeutic and hence com-
mercial success, lifting the Genzyme Corporation to among 
the world’s largest biotechnology companies and feeding 
blockbuster revenues into its burgeoning fortune. In 2008, 
the total revenue of Genzyme was US$4.5 billion, of which 
sales of Cerezyme amounted to ~US$1.2 billion. In Europe, 
Cerezyme was licensed under the newly introduced orphan 
medicinal products legislation for the chronic neuronopathic 
type III variant of Gaucher disease, where it also improves Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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life quality, as well as the hematologic manifestations and 
visceral engorgement.9,36,37
Biosimilar protein agents
The term ‘biosimilar’–otherwise known as ‘follow-on’ 
biologic agents–is used to describe approved new versions 
of innovative biopharmaceutical products following patent 
expiry. With respect to the current position of Cerezyme, 
the designation may be disputed in the industry. Although 
Cerezyme remains the standard care for the treatment of 
Gaucher disease and there is a burgeoning literature on its 
use over time in the mature phase of enzyme therapy,35–38 
two emerging biosimilar agents, also based on the prin-
ciple of macrophage targeting through the mannose lectin 
membrane receptor system, have been introduced. The first 
of these, velaglucerase-alfa (VPRIV®), was generated by a 
rival company, originally Transkaryotic Therapies, now taken 
over by Shire Human Genetic Therapies (Dublin, Ireland).39 
This agent is generated by gene activation of the endogenous 
human glucocerebrosidase gene in an immortalized human 
fibrosarcoma cell line. The engineered cells are cultured 
in a medium containing the powerful inhibitor kifunesine, 
which blocks the action of one of the processing glycosi-
dases for glycoprotein biosynthesis, and as a result, a human 
glucocerebrosidase protein displaying terminal mannose 
sugars is produced. The other biosimilar agent in late-phase 
development is taliglucerase-alfa, an agent licensed by the 
Protalix company, based in Israel. Taliglucerase is produced 
as a recombinant glycoprotein expressed in genetically engi-
neered plant cells.40 To secure secretion through the vacuolar 
pathway, the protein is modified: it harbors additional amino 
acids, as well as xylose and other sugars in its intermediate 
glycan sequence. Clinical trial data, now fast emerging from 
these products, indicate therapeutic activity in type I Gaucher 
patients attributed also to targeted delivery and uptake by 
tissue macrophages.39–41
Disadvantages of enzyme replacement therapy
Contrary to expectations, hypersensitivity and immune reac-
tions directed against the therapeutic proteins in type I Gau-
cher disease are very rare, and ,1% of patients with this form 
of the condition manifest resistance to enzyme therapy. Not 
surprisingly, the neurological manifestations of Gaucher dis-
ease are not corrected by enzyme therapy – a failure attributed 
to the blood–brain barrier which is largely impermeable to 
proteins. However, in rural areas and undeveloped countries, 
the requirements for intravenous infusion pose difficulties 
for administration and delivery of treatment – often even the 
supply of sterile needles and infusion apparatus presents a 
challenge. In addition, the high intrinsic costs of biological 
and other therapies for Gaucher disease are discussed below. 
Despite its salutary effects and reversal of the hematopoietic 
factors of Gaucher disease, enzyme therapy has limitations 
and only a proportion of patients achieve their therapeutic 
goals.38,42 Enzyme therapy has no direct therapeutic effect on 
the neurological manifestations of Gaucher disease.43–45
Finally, it must be admitted that intravenous infusions 
are not the preferred means of therapy for many patients 
who, given the choice, would prefer an orally active agent to 
the perceived invasiveness, inconvenience, and discomfort 
and apparent ‘medicalization’ signified by an intravenous 
treatment.
Substrate depletion (inhibitor) therapy
As with enzymatic augmentation, this approach to therapy 
is based on sound biochemical principles; it moreover 
represents a telling example of scientific translation into 
clinical practice within a fiercely competitive orphan 
disease niche.
The concept of substrate depletion therapy in the gly-
cosphingolipid diseases, of which Gaucher disease is an 
example, was introduced by Norman Radin and colleagues in 
the late 1970s,46,47 but it is based on a principle also adopted 
by Akira Endo and collaborators for the treatment of ath-
erosclerosis due to hypercholesterolemia. Endo discovered 
and developed the class of fungal metabolites now known as 
statins used widely to inhibit cholesterol biosynthesis.48
Since the inability to break down complex glycosphin-
golipids is the proximate cause of Gaucher disease and held 
to be the principal factor in its pathogenesis, inhibitors to 
decrease the biosynthesis of the substrate (glucosylceramide) 
should evince therapeutic benefit. Given that most patients 
have residual glucocerebrosidase activity, attenuating bio-
synthesis should allow this remaining enzymatic function 
to reduce steady-state concentrations of undegraded mac-
romolecular substrate within lysosomes and, by rebalancing 
glycosphingolipid metabolism, ultimately correct the dis-
ease. The biochemical target for this stratagem in Gaucher 
disease is the first committed step for glycosphingolipid 
biosynthesis catalyzed by uridine diphosphate (UDP) glu-
cosylceramide synthetase (UDP-glucose: N-acylsphingosine 
transferase).47–49 Two chemical classes of inhibitor are 
undergoing comprehensive therapeutic exploration: these are 
iminosugars derived from naturally occurring plant products 
and another class of compounds containing a pyrrolidine ring 
that serve as ceramide analogs.Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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Miglustat
The original compounds synthesized by Radin and col-
leagues were useful experimental inhibitors of the UDP-
glucosylceramide synthase, but because of their appreciable 
cellular toxicity, they were not initially developed for further 
clinical application.50 It was the iminosugars, in   particular 
N-butyldeoxynojirimycin, previously explored for an 
  unrelated application in HIV infection, which were identi-
fied for clinical development by Frances Platt and Terry 
Butters at the University of Oxford.51,52 They recognized 
that micromolar concentrations of N-butyldeoxynojirimycin 
inhibited the biosynthesis of glucosylceramide in cultures of 
a murine macrophage cell line treated with an irreversible 
inhibitor of acid-β-glucocerebrosidase, conduritol-β-epoxide. 
This agent induces lysosomal abnormalities, accompanied 
by an accumulation of glucosylceramide but coaddition of 
N-butyldeoxynojirimycin abrogated the lysosomal storage. 
Subsequent animal studies were conducted in knock-out 
mice lacking β-hexosaminidases, with accumulation of 
GM2 ganglioside in the brain.53 A strain of these animals, 
the Sandhoff mouse, has a shortened life expectancy with 
neurological manifestations, accompanied by progressive 
storage of GM2 ganglioside throughout the central neuraxis. 
The administration of N-butyldeoxynojirimycin reduced 
ganglioside storage in peripheral organs and brain of these 
animals and extended their survival by ∼40%.54
These preclinical studies, combined with earlier clinical 
trials in humans with HIV infection, stimulated the design 
of a clinical trial of N-butyldeoxynojirimycin (now known 
as miglustat or Zavesca®) in patients with type I Gaucher 
disease.55 At a dose of 100 mg thrice daily, the agent reduced 
visceral enlargement and slowly improved hematologic 
parameters, as well as surrogate plasma biomarkers, in 
patients with type I Gaucher disease.56–58 An unwanted effect 
of the iminosugar treatment was diarrhea, caused by an 
inhibition of intestinal disaccharidase activity. Some patients 
also developed tremor and/or peripheral neuropathy, but the 
drug has been licensed in the United States and Europe as 
a second-line treatment for patients with mild to moderate 
type I Gaucher disease.59
A recent study of its use in 28 patients with Gaucher 
disease who have been previously stabilized with enzyme 
therapy reported long-term findings with respect to organ 
size, blood counts, biomarkers, bone marrow infiltration, 
and safety, as well as tolerability. Assessments during 
routine clinic visits were carried out at 6, 12, 24, 36, and 
48 months after initiating treatment with miglustat. Biomark-
ers improved up to 48 months after initiation of miglustat, 
while other parameters were reported to be stable. Miglustat 
was considered to have acceptable safety and tolerability 
and to be effective for the long-term maintenance of this 
group of patients with type I Gaucher disease who had previ-
ously received enzyme   therapy.60 While the authors of this 
report contend that their study represents ‘real-life’ clinical 
  experience in the era after introduction of Ceredase and 
Cerezyme, the failure to distinguish the effects of miglustat 
from the course of type I Gaucher disease after long-term 
treatment (stabilization) with enzyme therapy or the con-
founding influence of patient   selection, detracts from the 
scientific clarity of this study.
Since in some strains of mice the agent leads to a nongeno-
toxic sterility of males, strict contraception is advised and 
the drug is not licensed for use in children.61–63
With the potential for the small iminosugar molecule 
to penetrate the blood–brain barrier, a further trial was 
conducted in children with chronic neuronopathic Gaucher 
  disease. However, this trial failed to meet its clinical end 
points and the drug currently is not recommended for neu-
rological manifestations in Gaucher disease;64 it is unknown 
as to whether or not it would be effective at higher tolerable 
doses in humans. Of interest miglustat  Zavesca has recently 
received a license in Niemann–Pick disease type C, another 
lysosomal disease affecting the brain in which disturbed 
cholesterol trafficking to lysosomes causes secondary accu-
mulation of glycosphingolipids in neurons.65 Since there is 
no other effective treatment for this devastating neurodegen-
erative disorder, Zavesca delivers, in part at least, an unmet 
clinical need for patients and their families otherwise without 
hope. Zavesca was first developed by Oxford Glycosciences 
(Oxon, UK) and is now licensed for marketing under the 
orphan drug legislation by the Actelion company (Allschwil, 
Switzerland).
eliglustat tartrate (Genz-112638)
James Shayman and colleagues in the University of Michigan 
and a former student of Norman Radin identified high-affin-
ity inhibitors of the metabolic target of glycosphingolipid 
synthesis, UDP-glucyosylceramide synthase.66 Homologues 
of the most potent inhibitors were generated as highly selec-
tive inhibitors of the enzyme, with inhibitory concentrations 
in the nanomolar range, but without appreciable cytotoxicity 
in culture. Cytotoxicity appears to be related to increased 
ceramide concentrations in cells, attributed to nonselective 
inhibitory effects of the prototype agents on a previously 
unknown ceramide transacylase activity. Intensive screening 
of isomers of a parent compound led to the generation of Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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Genz-112638, recently developed as eliglustat tartrate by 
the Genzyme Corporation.67 Medicinal chemists within the 
company invented the means for efficient enantioselective 
syntheses of the highly selective inhibitory isomers, which 
are held under patent.68 The compound chosen for develop-
ment is a structural analog of   d-threo-ethylinedioxypheny
l-2-palmitoylamino-3-  pyrrilidino-propanol   formulated as 
a salt of tartaric acid. The full chemical name of eliglustat 
tartrate is (1R, 2R)-Octanoic acid [2-(2′,3′-  dihydro-benzo[1
,4]  dioxin-6′-yl)-2-hydroxy-1-pyrrolidin-1-ylmethyl-ethyl]-
amide-l-tartaric acid salt.
This agent, as a free base, is metabolized by the cyto-
chrome P450 system and in several cell lines has a powerful 
inhibitory action on UDP-glucose: N-acylsphingosine trans-
ferase with an IC50 of 24 nanomolar.67 At low micromolar 
concentrations, it has no appreciable inhibitory action on 
intestinal sucrase and maltase activities or lysosomal acid 
β-glucocerebrosidase. Preclinical studies were conducted 
in a murine model of Gaucher disease (gbaD409V/nul), which 
develops occasional storage cells in viscera in associa-
tion with lysosomal accumulation of glucosylceramide.69 
  Eliglustat tartrate is a substrate for the P-glycoprotein multi-
drug transporter and so does not accumulate in brain tissue of 
normal rodents. It was shown to have satisfactory preclinical 
toxicology in experimental animals.
Phase I studies have been conducted in 99 human subjects, 
with doses of 50–200 mg given twice daily inducing plasma 
concentrations of the agent within the predicted therapeutic 
range.70 Although in preclinical studies the agent may have 
an effect on cardiac conduction intervals, this effect does 
not appear to be significant at therapeutic dosing levels. The 
drug is metabolized principally by the CYP2D6 cytochrome, 
thus careful monitoring will be prudent in patients taking 
other drugs known to interact with this metabolic pathway 
of degradation. Such drugs include paroxetine, ketoconazole, 
and rifampicin.
After satisfactory Phase I clinical trials in healthy human 
volunteers, Phase II clinical studies were undertaken, and 
information is available from patients having completed 
2 years of therapy.71,72 These trials were undertaken in adults 
with type I Gaucher disease, for which the entry criteria 
required splenic enlargement of at least 10-fold normal, 
together with thrombocytopenia and/or anemia. The dose of 
drug was either started at 50 mg twice daily or with monitor-
ing for pharmacokinetics adjusted to 100 mg twice daily to 
ensure that rapid metabolizers would have concentrations of 
the drug of ≈10 ng/mL. A composite primary efficacy end 
point, based on two of the three parameters (spleen volume, 
hemoglobin concentration, and platelet count), was used; 
furthermore, dual-energy X-ray absorptiometry studies 
with T1-weighted MRI of femurs were undertaken. There 
was extensive safety monitoring, particularly for untoward 
neurological effects and cardiac events.72
Outcome measures
Of the 22 patients who completed the trial at 1 year, 20 
attained the composite primary therapeutic end point, with 
improvements of at least two of the three abnormal values 
initially present. No bone crises occurred, and there were no 
changes in mobility, in bone pain, or on X-ray examination. 
There were, however, early signs of improvement in magnetic 
resonance imaging of bone marrow signal (dark marrow) at 
2 years of treatment. Twenty of the original 26 patients had 
completed the therapy and most remain on an extended trial. 
Continuing improvement in spleen and liver volumes (the for-
mer decreased by a mean of 52%) with improvement in 
hemoglobin concentration and a rise in platelet counts have 
been observed. All these changes were accompanied by 
salutary improvements in surrogate biomarkers, including the 
chemokine CCL18-PARC and chitotriosidase activity. Of the 
18 patients with abnormal dark signal independently identi-
fied on magnetic resonance imaging, six had improved by 1 
year and an additional two patients had shown improvements 
by 2 years on the trial.72 Further promising effects on bone 
mineralization density were seen with significant increases 
noted in most patients.
The safety profile and efficacy of eliglustat in patients 
with moderate Gaucher disease and the salutary effect on 
bone mineral density and abnormal bone marrow signals have 
prompted initiation of several multicenter Phase III studies. 
The first of these trials is a randomized, open-label study for 
adults with type I Gaucher disease, designed to compare the 
efficacy and safety of eliglustat tartrate with that of Cerezyme. 
Recruited patients should have received enzyme therapy for 
at least 3 years and have achieved clinical stability by reach-
ing key therapeutic goals in terms of blood counts, visceral 
volumes, and bone status. The second trial is a randomized, 
blind, placebo-controlled study for patients with a confirmed 
diagnosis of type I Gaucher disease, who have not been treated 
for at least 12 months. A final trial has been registered, which 
will seek to compare the effects of one daily dosing of eliglustat 
tartrate with twice daily administration.
Pharmacological chaperone therapy
The pharmacological chaperone concept is based on the 
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that are misfolded and thus prevented from realizing their 
normal intracellular activity. Abnormal protein folding has 
been recognized as a common molecular mechanism in many 
inherited diseases and leads to premature   degradation of 
the newly synthesized protein in the endoplasmic reticulum 
and also within the Golgi complex. In the case of lysosomal 
enzymes, the chaperone concept involves the binding of 
the agent to the active site of the mutant lysosomal protein, 
thus stabilizing it for delivery to its normal site of action 
in the acidic environment of the organelle. Chaperone mol-
ecules are thus often weak inhibitors which bind at neutral 
pH during biosynthesis of the enzyme and stabilize it for 
delivery to the lysosome; in the lysosome, the dramatic 
increase in hydrogen ion concentration is proposed to favor 
  dissociation of the inhibitor, thus allowing restitution of 
enzyme function.73
Another iminosugar, isofagomine, shows pharmacologi-
cal chaperone activity directed toward glucocerebrosidase 
in fibroblasts cultured from type I Gaucher patients. This 
agent has been developed for Phase I/II clinical trials in 
Gaucher patients by the Amicus company (Cranbury, NJ). 
Although the drug was moderately well tolerated, apart from 
inducing conjunctivitis in some subjects, the first trial, with 
intermittent dosing as required for a putative pharmacologi-
cal chaperone, showed disappointing therapeutic outcomes. 
The Amicus company continues with its trials, in particular 
with a similar iminosugar (1-deoxygalactonojirimycin) 
to investigate its possible therapeutic action on mutant 
α-galactosidase A in the related lysosomal disease, 
  Anderson–Fabry disease.73
Gene therapy
While in the context of enzyme therapy, which is safe 
and effective, the risks of bone marrow transplantation or 
hematopoietic stem-cell therapy render cellular complemen-
tation impractical for general application in most patients 
with Gaucher disease, the same stringencies might not 
be obtained for gene therapy using lentivirus-transduced 
autologous hematopoietic stem cells. If used for Gaucher 
disease, as reported for the neurodegenerative disease 
adrenoleukodystrophy74 and currently in clinical trials for 
presymptomatic metachromatic leukodystrophy in infants 
and children, such an approach would have the advantage 
of being a one-off procedure requiring less powerful myelo-
ablative conditioning and thus attractive for patients predicted 
to be at risk of severe disease and originating from countries 
where the availability, monitoring, or delivery of enzyme 
therapy is unsatisfactory.
Early clinical trials of macrophage-directed glucoce-
rebrosidase using first-generation lentiviral gene transfer 
vectors in two centers were disappointing with very low 
transduction efficiencies and/or early shutoff of   corrective 
gene expression in circulating monocytes; no clinical benefit 
was reported. These results were particularly disappoint-
ing since a bicistronic retroviral vector expressing human 
glucocerebrosidase and a human small cell surface antigen 
(CD24) as a selectable marker, under the control of the 
Moloney murine leukemia viral promoter, were used to 
transform CD34+ hematopoietic progenitors.75 Latterly, there 
have been promising preclinical developments in the gene 
therapy of type I Gaucher disease from Stefan Karlsson and 
colleagues at the University of Lund, Sweden. This group 
was the first to generate a convincing inducible mammalian 
model of the disorder in the hematopoietic system and major 
viscera of genetically engineered mice;76 they have further 
utilized this model as a test system to evaluate lentiviral gene 
therapy directed to autologous hematopoietic stem cells using 
busulfan for nonablative pretransplant conditioning without 
whole body irradiation. With this stratagem, they were able 
to demonstrate that stem-cell engraftment in the range of 
1%–10% wild type confers clear benefit in this authentic 
disease model.77
While there may be residual safety issues surrounding 
the use of lentiviral vectors directed to proliferating cel-
lular compartments, the capacity permanently to correct 
the principal manifestations of the condition with a minor 
proportion of autologous stem cells corrected by gene 
transfer is a signal advance.77 Recent studies on the use of 
third-generation self-inactivating (SIN) lentiviral vector 
derivatives in patients with adrenoleukodystrophy with 
random, rather than preferential, integration at sites with 
the potentiality for oncogenesis in the human genome are 
also critically important for issues of safety.74,75 However, in 
the recent clinical use of SIN lentiviral vectors to transduce 
autologous CD34+ hematopoietic stem cells in two boys with 
adrenoleukodystrophy by Cartier and colleagues, a complete 
myelo-ablative regimen was employed.
A further approach to the definitive treatment of non-
neuronopathic Gaucher disease (type I) in effect combines 
gene therapy with systemic enzymatic complementation. In 
a stratagem using adeno-associated viral (AAV)-mediated 
gene therapy, McEachern and colleagues78 administered a 
recombinant AAV8 serotype vector harboring the human 
β-glucocerebrosidase gene under the control of a liver-
  selective promoter intravenously to D409V/null mice with 
features of Gaucher disease. The vector induced sustained Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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hepatic secretion of the enzyme, which was sufficient to 
  prevent accumulation of glucosylceramide and Gaucher 
cells in the liver, spleen, and lungs of young animals and 
had marked benefit on these parameters in older mice with 
established disease. The absence of antibodies on challenge 
indicated that the animals had been tolerized to the thera-
peutic protein. Such a strategy would also lend itself to the 
application of gene therapy to patients with Gaucher disease: 
it has the potential advantage of not requiring myelo-ablative 
therapy and ease of administration for what would be envis-
aged as a one-off procedure. A key requirement, however, 
would be sustained expression of the therapeutic gene in 
hepatocytes transduced by the rAAV vector – an issue that 
has yet to be overcome in relation to gene therapy for hemo-
philia.79 Given the current state of knowledge and preclinical 
studies, credible clinical trials could soon be initiated; but the 
location of   appropriate investigative centers and selection of 
patients will be of critical importance.
Discussion
Predictable and unexpected  
effects of orphan drug legislation
While the orphan drug legislation was designed to pro-
vide strong incentives for pharmaceutical development in 
neglected and rare diseases, the commercial rewards realized 
in a very rare (ultraorphan) condition, Gaucher disease, were 
unforeseen and unprecedented. The incentives have been 
keenly felt by several companies seeking similar trophies; 
they have sought also to position themselves in the field by 
acquisition.
Access and cost
There can be no doubt that the general outlook for patients 
with Gaucher disease and related lysosomal diseases 
for which enzymatic augmentation has been introduced 
(as well as initiatives involving small molecule inhibitors 
and   chaperones) has improved immeasurably; these benefits 
extend only to those patients for whom insurance and national 
health care provision is available. Only a minority (≈10%) 
of patients with Gaucher disease worldwide are fortunate 
enough to have access to enzyme replacement therapy, 
principally because of the extreme cost of this ultraorphan 
treatment for each patient. To capitalize on its leading posi-
tion and sustain a program of therapeutic development, 
Genzyme charges highly for products provided to only a few 
thousand patients internationally: the average cost to treat an 
adult Gaucher patient with enzyme therapy is of the order 
of £100,000 and in the early debulking phases of the illness, 
about £200,000 per annum.
Development costs
Although it is claimed that the introduction of a new biologi-
cal drug may cost $500,000–$1,000,000,000, in the case of 
alglucerase (Ceredase) for Gaucher disease, the manufacturer 
reported spending less than $58M for development. However, 
we should remember that this was 20 years ago and the bur-
den of costs was shared with academia. Given the prolonged 
marketing exclusivity awarded for the first introduction of 
an orphan agent of 7 and 10 years in the United States and 
Europe, respectively, the potential rewards for each corporate 
winner are high. While those developing biosimilar drugs 
must bide their time or demonstrate that their products have 
unequivocal therapeutic advantages, companies with an 
active discovery portfolio can steal an advantage if their drug 
has an innovative mode of action, as illustrated by the sub-
strate inhibitors. Since it was first proposed, progress on gene 
therapy has been slow, even for monogenic diseases in which 
it clearly offers the potential for a definitive and specific cure. 
It is salutary to recall that more than two decades ago, the 
original scientific board of the corporation advised the man-
agement of Genzyme not to proceed with the development of 
enzyme therapy because gene therapy for the condition was 
so far advanced at the time. Perceptions of advantage and 
the real nature of competition in orphan diseases remain – as 
with all aspects of biotechnology – fraught with the foibles 
of human judgment and error.
Clearly, after a time, strong incentives also re-emerge 
for oncoming competitors with biosimilar protein agents, 
since by following the data of the innovator, development 
costs may be reduced to a scale of tens rather than hundreds 
of millions of dollars.
The value and safety implications  
of competition
We now also know that there is a previously unrecognized 
clinical advantage provided by alternative biological agents, 
for example velaglucerase-alfa and taliglucerase-alfa in Gau-
cher disease – a guaranteed safety of supply. The necessity 
of competing alternatives has emerged as a result of a cata-
strophic year-long shortage of Cerezyme, resulting from a 
vesivirus infection occurring in the dedicated bioreactor plant 
at the principal production facility of the Genzyme Corpora-
tion in Allston, Massachusetts, in June 2009.80 At the time, 
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stage of clinical development, their ready availability for 
several hundred patients in Europe and the United States has 
partially mitigated the crisis both for the patients and their 
treating physicians, as well as the prowess of the Genzyme 
Corporation. In the face of this crisis, many physicians and 
regulatory agencies worked with all the commercial partners 
to promote release of the new enzyme preparations through 
compassionate access programs before licensing to expedite 
the regulatory processes for licensing approval and to accel-
erate approval for distribution in the United States, Europe, 
and other regions, wherever possible.
The competitive niche
Biological treatments, such as enzymatic augmentation 
in lysosomal disorders, can be challenged by competitive 
small molecules, as has been convincingly demonstrated in 
  Gaucher disease. The innovation of substrate depletion ther-
apy with biosynthetic inhibitors of the principal   glycolipids, 
which accumulate in macrophages, provides an attractive 
scientific and pharmaceutical alternative. Not only are such 
compounds more readily distributed and administered, but 
their mode of action is distinct and a compelling advantage 
in competition.
Other powerful advantages include the generally cheaper 
manufacturing costs of small molecular compounds, as com-
pared with human enzyme preparations, which in the case 
of Gaucher disease require elaborate modification to ensure 
appropriate targeting to the affected tissues (macrophages) 
in vivo. While the Actelion drug, miglustat (Zavesca), is cur-
rently seen as a second-line agent for Gaucher disease,59,63 its 
inception clearly directed Genzyme to innovative departures, 
based on a distinct chemistry. Genzyme has made a large 
investment through numerous patents on the synthesis of its 
novel ceramide-like selective inhibitor of a novel biochemi-
cal target; and one wonders if it would have done so had a 
competing orally available agent with a novel mechanism of 
action not come to light.
In relation to pharmacological chaperone therapy, as yet 
in an undeveloped phase for clinical practice, it can be seen 
that the innovative drive and incentive for developing new 
therapies in Gaucher disease is pervasive and strong. With-
out it, much pharmaceutical development for needy patients 
with disorders otherwise lacking specific measures would not 
have occurred. While enzyme replacement therapy undoubt-
edly provides large measurable health gains for adults and 
may prevent disease if given sufficiently early in children, 
we must recognize that some accommodation is needed in 
our appreciation of pharmaceutical ‘miracles’. After all, if 
all rare diseases mandated such enthusiastic pharmaceuti-
cal interest, the costs of diverting health care resources to 
swell the revenues of pharmaceutical companies could not 
be sustained.
Pricing issues
The prices set by pharmaceutical companies for their drugs 
are arrived at by complex and obscure means, but are 
justified by the need to cover the costs of production and 
accompanying investment in the light of competing agents. 
The perception of health benefits is also an important factor 
in price setting. The need to generate profit is an unqualified 
but critical factor. In the case of orphan agents, the unmet 
need is construed as very high and unchallenged, for there 
is by definition no competition which would otherwise 
mitigate pricing. Although biological agents notionally 
would be expected to be very costly, the economy of scale 
and long-standing marketing exclusivity with, for example, 
the production of a genetically engineered protein from cell 
cultures quickly allows an astonishing profit margin to be 
achieved.
issues of marketing exclusivity
Gaucher disease provides here another vivid example, not 
only of the triumph of Western capitalist principles of utility 
and progress linked to profit, but of a market exclusivity of 
another kind. For such are the prices of the drugs developed 
in Western democratic countries that the public health care 
systems of other populations do not even aspire to meet 
them. It will be recalled that Stalin commuted the salaries 
of doctors and other health care personnel greatly: even 
after the fall of Stalin and two decades after the collapse 
of the Communist system in Russia and post-Soviet states, 
exiguous salaries and investment have given rise to appalling 
state provision for health. At the same time, private medi-
cal services for party members and emerging plutocrats in 
Russia and many former Communist countries aspire to the 
best international standards of delivery and comfort. Under 
these circumstances, for many patients, access to expensive 
treatments such as Cerezyme for Gaucher disease is either 
denied or highly restricted.
Compassionate supply
The problem of access has been commendably addressed in 
the divisional locations of Genzyme in capitalist countries 
by the introduction of free compassionate use programs for Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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severely ill Gaucher patients resident in communities where 
health care systems do not reimburse the costs of lifesaving 
therapy. However, this does not address the total need of 
Gaucher patients worldwide, for it is estimated that of the 
5000 or so patients who have been treated with Cerezyme 
(until the recent shortage caused by vesivirus infection and 
shutdown of Genzyme’s Allston plant80), this would represent 
a maximum of 10% of all symptomatic Gaucher patients.
Orphan drug pricing
While the high cost of manufacturing biological agents has 
the appearance of veracity, one should also expect the com-
peting small molecules to be made available at costs that are 
substantially less than those for enzyme therapies. There is 
only one example for a direct comparison, namely Zavesca,   
at a cost of ∼$100,000 per year for an average adult. It is thus 
clear that incentive and shareholder revenue overshadow the 
costs of manufacture for nonbiological agents even in the 
orphan drug field.
The concept of ‘pile them high and sell them cheap’ 
has yet to emerge among the competitors of first-to-market 
orphan drugs, but where access remains difficult for many 
patients in less developed countries, this heretical idea 
  arguably merits consideration.
Conclusion
Future considerations for orphan 
drug development
Market-driven economies reward value and should aspire 
to reward the value that health – a basic human necessity – 
brings to its citizens.
Some patients with rare diseases have now received 
welcome attention through the agency of orphan drug 
legislation, and in many cases, they gain real benefit as 
a result of pioneering humane initiatives. Nonetheless, 
the current model will need reviewing if it is to deliver value 
across the thousands of individually rare diseases in whole 
populations.81
As illustrated by the remarkable example of Gaucher dis-
ease, orphan drug legislation can, in effect, promote vulner-
able monopolies and also has other unintended consequences. 
Once licensed, beyond mandatory pharmacovigilance 
monitoring and fulfilment of postlicensing commitments, 
there is little incentive for the victorious company to invest 
in therapeutic research into the cognate disease. For such 
investment to occur, competition and the fear of loss of 
commercial primacy need to be felt, for only strong survival 
instincts and the need to demonstrate prowess will induce 
further scientific expenditure.
Orphan drug legislation is anticompetitive, but we now 
know that even this cannot guarantee the survival of any given 
drug, particularly a biologic agent like a therapeutic enzyme: 
there can be no immunity from unexpected manufacturing 
disasters. In the case of Gaucher disease, the catastrophic 
vesivirus infection that has all but stopped   production of 
Cerezyme for most of the year from June 200980 (as well as 
Genzyme’s agent for Fabry disease, Fabrazyme®) leading to 
a reported 34% fall of Cerezyme sales to $793 million, while 
sales of Fabrazyme fell 13% to $494 million. The company 
is struggling now to recover its inventory while supplying 
as many of its global customers as possible: the catastrophe 
has brought home not simply the desirability but the absolute 
necessity of competition for the safe provision of alternative 
biosimilar agents.
Much has been learned from the modern miracle of 
  Gaucher disease as an orphan disorder, but at the time of 
writing, we are entering a period of radical change. With a 
history of unresolved regulatory issues involving produc-
tion at their impressive manufacturing plant after FDA 
inspections, the sudden appearance of a vesivirus infection 
at the Allston facility has exposed the Genzyme Corpora-
tion to intense scrutiny; the reputation of an inspirational 
leader in the field has been publicly questioned. Moreover, 
Genzyme has had to bear hostile bids in the ruthless com-
mercial world of industrial takeovers – and in times when 
pharmaceutical giants are cutting their own research and 
development budgets in favour of acquiring successful 
biotech companies with more innovative approaches to rare 
diseases (‘niche-busting’). Although there can be no retreat, 
at a time of unparalleled opportunity and competitive interest 
in rare disorders, some form of societal reckoning to ensure 
sustainable innovation in the whole field – of which Gaucher 
disease is emblematic – is surely warranted.1 Imaginative 
approaches will be needed to commute the prices of orphan 
drugs in a mature market, so that hand-in-hand therapeutic 
discovery and development can be maintained in the long 
term at the current unprecedented level of productivity and 
clinical benefit.
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